Abstract
This study investigated the role of cancer/testis antigen DDX53 in regulating cancer stem cell-like properties. DDX53 shows co-expression with CD133, a marker for cancer stem cells. DDX53 directly regulates the SOX-2 expression in anticancer drug-resistant Malme3MR cells. DDX53 and miR-200b were found to be involved in the regulation of tumor spheroid forming potential of Malme3M and Malme3MR cells. Furthermore, the self-renewal activity and the tumorigenic potential of Malme3MR-CD133 (+) cells were also regulated by DDX53. A miR-200b inhibitor induced the direct regulation of SOX-2 by DDX53 We therefore, conclude that DDX53 may serve as an immunotherapeutic target for regulating cancer stem-like properties of melanomas.
Keywords:
DDX53; SOX-2; anti-cancer drug-resistance; cancer stem cell-like properties.
MeSH terms
-
AC133 Antigen / metabolism
-
Animals
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Cell Line, Tumor
-
DEAD-box RNA Helicases / genetics
-
DEAD-box RNA Helicases / metabolism*
-
Drug Resistance, Neoplasm / drug effects
-
Drug Resistance, Neoplasm / genetics
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Melanoma / metabolism
-
Melanoma / pathology
-
Mice, Inbred BALB C
-
MicroRNAs / genetics
-
Neoplastic Stem Cells / metabolism
-
Neoplastic Stem Cells / pathology*
-
Paclitaxel / pharmacology
-
SOXB1 Transcription Factors / genetics
-
SOXB1 Transcription Factors / metabolism*
-
Xenograft Model Antitumor Assays
Substances
-
AC133 Antigen
-
Antineoplastic Agents, Phytogenic
-
MIRN200 microRNA, human
-
MicroRNAs
-
PROM1 protein, human
-
SOX2 protein, human
-
SOXB1 Transcription Factors
-
DDX53 protein, human
-
DEAD-box RNA Helicases
-
Paclitaxel